Last reviewed · How we verify
NCT07453953
A Comparison of Clinical Efficacy of Mytocel MSK With AMT and PRP Injections in Patients With Knee Osteoarthritis
EARLY_PHASE1 trial testing PRP in Mytocel MSK With AMT in 30 participants. Not yet recruiting.
31 December 2028
Quick facts
| Lead sponsor | Taichung Veterans General Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 April 2026 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2030 |
Drugs / interventions tested
- PRP — full drug profile →
Conditions studied
- Mytocel MSK With AMT — all drugs for Mytocel MSK With AMT →
Sponsor
Taichung Veterans General Hospital
Who can join
Adults 18 to 80, any sex, with Mytocel MSK With AMT. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Osteoarthritis is the most common joint disease, frequently affecting the knee joint. As the cartilage within the joint wears down, the balance between degeneration and regeneration is gradually disrupted, causing pain during joint movement. Mytocel MSK with AMT (Autologous Micrograft Technology) is an autologous micrograft technology, the first biocompatible solution that can be directly implanted into the joint using the patient's own tissue. It possesses regenerative repair and pain-relieving effects, rapidly improving joint health and alleviating pain and stiffness. It is primarily applied to the musculoskeletal system; this therapy has been proven to have tissue regeneration potential and effectiveness in multiple medical fields. This project will harvest ear cartilage tissue, mechanically separate and precisely filter it to create a Mytocel MSK with AMT cell suspension rich in cartilage precursor cells and mesenchymal stem cell markers (CD44, CD90, CD117), which will then be injected into the knee joint cavity. It is expected to help patients repair cartilage, reduce pain, and improve their quality of life. PRP is a common treatment for knee osteoarthritis, but its effects are short-lived and require multiple injections. Mytocel MSK with AMT may achieve longer-term and more stable clinical improvement with a single application. This project will use questionnaires and MRI examinations to observe changes in pain, functional recovery, and the degree of cartilage repair before and after treatment. The data will be used to analyze and compare the differences between Mytocel MSK with AMT and PRP treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07453953
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PRP
Trials testing the same drug.
- NCT07565844 — Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia · NA · recruiting
- NCT06384859 — Effectiveness of Extracorporeal Shockwave Therapy Combined With Platelet-rich Plasma in the Treatment of Chronic Inserti · Phase 4 · not yet recruiting
- NCT06339645 — Intravesical Platelet-rich Plasma Injection in Patients With Interstitial Cystitis/Bladder-A Retrospective Study · unknown
- NCT06332352 — Intra-articular Platelet-Rich Plasma for Acetabular Labral Tears · NA · completed
- NCT06234540 — a-PRP Intrauterine Instillation in Women With Thin Endometrium · NA · unknown
Other Taichung Veterans General Hospital trials
Trials by the same sponsor.
- NCT06858436 — SGLT2 Inhibitor Utilization Re-perfusion Therapy · Phase 4 · not yet recruiting
- NCT07487636 — 4DryField PH and Head and Neck Operations. · NA · enrolling by invitation
- NCT07284017 — The Impact of Neuronavigation in rTMS for Hemiplegic Stroke Patients. · NA · not yet recruiting
- NCT07363876 — The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis · NA · not yet recruiting
- NCT07479147 — SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07453953 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taichung Veterans General Hospital
- Last refreshed: 6 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07453953.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing